To evaluate the efficacy and safety of insulin glargine 300U/mL (Gla-300) versus glargine 100U/mL (Gla-100) in adults with type 1 diabetes in Japan over 12months.EDITION JP 1 was a multicentre, randomised, open-label phase 3 study. Following a 6-month on-treatment period, participants continued to receive Gla-300 or Gla-100 once daily, plus mealtime insulin, over a 6-month open-label extension phase. HbA1c, hypoglycaemia, body weight and adverse events were assessed.Overall, 114/122 (93
作者:Munehide, Matsuhisa;Masayoshi, Koyama;Xi, Cheng;Mariko, Sumi;Matthew C, Riddle;Geremia B, Bolli;Takahisa, Hirose
来源:Diabetes research and clinical practice 2016 年 122卷